tradingkey.logo

Lilly's Taltz Plus Zepbound Shows Superior Efficacy In Phase 3B Trial For Arthritis, Obesity

ReutersJan 8, 2026 7:19 PM

- Eli Lilly and Co LLY.N:

  • LILLY'S TALTZ (IXEKIZUMAB) AND ZEPBOUND (TIRZEPATIDE) USED TOGETHER DELIVERED SUPERIOR EFFICACY IN FIRST-OF-ITS-KIND PHASE 3B TRIAL FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT

  • ELI LILLY - TOGETHER-PSA STUDY MEETS PRIMARY ENDPOINT WITH 50% PSA IMPROVEMENT

  • ELI LILLY - TALTZ AND ZEPBOUND DELIVER 64% INCREASE IN ACR50 ACHIEVEMENT

  • ELI LILLY - ADVERSE EVENTS WITH TALTZ AND ZEPBOUND WERE MILD TO MODERATE

  • ELI LILLY - TOPLINE RESULTS FROM ONGOING TOGETHER-PSO TRIAL EXPECTED IN H1 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI